Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
0.979
+0.009 (0.89%)
At close: Mar 9, 2026, 4:00 PM EDT
0.979
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:04 PM EDT
Cardiol Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
18
Market Cap
105.90M USD
Revenue Chart
* This company reports financials in CAD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aurora Cannabis | 272.13M |
| Organigram Global | 204.21M |
| Assertio Holdings | 137.35M |
| Anika Therapeutics | 112.82M |
| InterCure | 72.16M |
| Journey Medical | 59.40M |
| Cumberland Pharmaceuticals | 41.28M |
| Alpha Teknova | 40.52M |
CRDL News
- 4 days ago - Cardiol Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
- 12 days ago - Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference - Newsfile Corp
- 27 days ago - Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure - Newsfile Corp
- 6 weeks ago - Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million - Newsfile Corp
- 7 weeks ago - Cardiol Therapeutics announces $13.5M bought-deal private placement - Seeking Alpha
- 7 weeks ago - Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million - Newsfile Corp
- 7 weeks ago - Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million - Newsfile Corp
- 7 weeks ago - Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis - Newsfile Corp